000169275 001__ 169275
000169275 005__ 20240229133646.0
000169275 0247_ $$2doi$$a10.1080/0284186X.2021.1940274
000169275 0247_ $$2pmid$$apmid:34137351
000169275 0247_ $$2ISSN$$a0284-186X
000169275 0247_ $$2ISSN$$a1100-1704
000169275 0247_ $$2ISSN$$a1651-226X
000169275 0247_ $$2ISSN$$a1651-2499
000169275 0247_ $$2altmetric$$aaltmetric:107798405
000169275 037__ $$aDKFZ-2021-01372
000169275 041__ $$aEnglish
000169275 082__ $$a610
000169275 1001_ $$0P:(DE-He78)a4307287511137778efe28e651f9f245$$aScherer-Trame, Sophie$$b0$$eFirst author$$udkfz
000169275 245__ $$aInpatient rehabilitation therapy among colorectal cancer patients - utilization and association with prognosis: a cohort study.
000169275 260__ $$aAbingdon$$bTaylor & Francis Group$$c2021
000169275 3367_ $$2DRIVER$$aarticle
000169275 3367_ $$2DataCite$$aOutput Types/Journal article
000169275 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1626337746_24713
000169275 3367_ $$2BibTeX$$aARTICLE
000169275 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169275 3367_ $$00$$2EndNote$$aJournal Article
000169275 500__ $$a#EA:C071#LA:C070# / 2021 Aug;60(8):1000-1010
000169275 520__ $$aInpatient rehabilitation therapy (IRT) is commonly offered to cancer patients during or after cancer treatment in Germany. However, little is known about utilization and long-term effects of this offer in colorectal cancer (CRC) patients. We aimed to assess IRT utilization, determinants of utilization and the association between IRT and survival in CRC patients.CRC patients diagnosed in 2005-2014 recruited in the population-based DACHS study in South West Germany were included. Determinants of IRT utilization were assessed by multivariable logistic regression. Hazard ratios (HRs) of the association of IRT with overall and disease-specific survival were estimated by adjusted Cox proportional hazards models. Modified landmark approach was applied to avoid immortal time biased results.Among the included CRC patients (n = 3704), 43.6% underwent IRT. Patients who did not live in a relationship with a partner, worked as employee and who reported higher levels of physical activity were more likely to undergo IRT. Patients were less likely to undergo IRT if they had private health insurance, were diagnosed with cancer stage IV, received no or laparoscopic cancer surgery or were treated in a hospital with medium vs. high surgical volume. The median follow-up time was 4.4 years (post-landmark). Utilization of IRT was associated with better overall (HR 0.81, 95% confidence interval 0.72-0.92) and disease-specific survival (HR 0.72, 95% confidence interval 0.61-0.85).Almost every other CRC patient underwent IRT. Next to clinical characteristics, identified social and lifestyle characteristics seemed to play an essential role in the decision-making. Use of IRT was associated with better overall and disease-specific survival.
000169275 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169275 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169275 650_7 $$2Other$$aInpatient rehabilitation
000169275 650_7 $$2Other$$acancer rehabilitation
000169275 650_7 $$2Other$$acolorectal cancer
000169275 650_7 $$2Other$$asurvival
000169275 650_7 $$2Other$$autilization
000169275 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b1$$udkfz
000169275 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b2$$udkfz
000169275 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b3$$udkfz
000169275 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b4$$udkfz
000169275 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author$$udkfz
000169275 773__ $$0PERI:(DE-600)1492623-4$$a10.1080/0284186X.2021.1940274$$gp. 1 - 11$$n8$$p1000-1010$$tActa oncologica$$v60$$x0001-6926$$y2021
000169275 909CO $$ooai:inrepo02.dkfz.de:169275$$pVDB
000169275 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a4307287511137778efe28e651f9f245$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000169275 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000169275 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169275 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000169275 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169275 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000169275 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000169275 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169275 9141_ $$y2021
000169275 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-30$$wger
000169275 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA ONCOL : 2019$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-30
000169275 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-30
000169275 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000169275 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000169275 9201_ $$0I:(DE-He78)M110-20160331$$kM110$$lM110 Epidemiologisches Krebsregister Baden-Württemberg$$x2
000169275 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x3
000169275 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x4
000169275 980__ $$ajournal
000169275 980__ $$aVDB
000169275 980__ $$aI:(DE-He78)C120-20160331
000169275 980__ $$aI:(DE-He78)C070-20160331
000169275 980__ $$aI:(DE-He78)M110-20160331
000169275 980__ $$aI:(DE-He78)C020-20160331
000169275 980__ $$aI:(DE-He78)HD01-20160331
000169275 980__ $$aUNRESTRICTED